Menu +

Corcept Therapeutics to Present at Thomas Weisel Partners Healthcare Conference on September 7, 2005

Corcept Therapeutics Incorporated (Nasdaq: CORT) today announced that the company will present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 7th at 1:30 p.m. (EDT) at the Four Seasons Hotel in Boston. The presentation will cover the company's clinical and corporate progress.

A live and subsequent archive of the Corcept presentation will be available on September 7, 2005 via webcast at:
The webcast will be available for 2 weeks.

About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Corcept's lead product, CORLUX®, is currently in Phase III clinical trials for the treatment of the psychotic features of psychotic major depression (PMD). The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. Corcept is also conducting a clinical trial to evaluate the safety and efficacy of our product in improving cognition in patients with mild to moderate Alzheimer's disease. For additional information about the company, please visit

Fred Kurland
Chief Financial Officer
Corcept Therapeutics

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue